Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
  • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
  • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
  • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
  • C07C2601/14—The ring being saturated

Definitions

• This invention refers to novel salts of
• (+)-(lS,2R)-2-[[N-(2-hydroxylamino-2-oxoethyl)-N-methyl-amino]carbonyl]cyclohexane- 1-carboxylic acid 1, (D.C.I. Idrapril) is a compound disclosed in the European Patent Application No. 89106304.2 as a novel ACE- inhibitory agent and therefore having antihypertensive activity.
• This acid when kept exposed to the air in the normal environmental conditions of humidity and temperature, is subject to autodecomposition processes which give rise to impurities obviously incompatible with regard to a therapeutical use. Such degradation processes are also accelerated by a temperature increase of the acid kept in the above conditions.
• novel salts according to this invention do not undergo to the autodecomposition and degradation processes previously mentioned.
• the salts of the invention are stable compounds in the normal environmental conditions. Further the salts remain unchanged with time either kept as such or included (in a solid state) in a pharmaceutical preparation (tablets, pills, capsules, lyophilized compositions and the like) provided for their therapeutical use.
• a pharmaceutical preparation tablettes, pills, capsules, lyophilized compositions and the like
• the preparation of the compounds of the invention is based on a process characterized in that a compound, selected between
• (+)-(1S,2R)-2-[[N-(2-hydroxyIamino-2-oxoethyl)-N-methylam ⁇ no]carbonyllcyclohexane-1 -carboxylic acid 1, is reacted with a compound selected among hydrates and carbonates or other suitable salts of alkaline and alkaline-earth metals, as defined in the present invention, as well as with organic bases, in an organic solvent or mixtures thereof with water, the reaction taking place, in the case of the starting product 2, contemporaneous hydrogenalysis of the protecting benzyl group with hydrogen at atmospheric pressure, in the presence of a suitable hydrogenation catalyst, the process being completed by isolating the desired salt of the acid.
• Q is said hydroxide, or alkaline salt or calcium salt or an organic base.
• the preferred hydrogenation catalyst is charcoal-supported Pd, but PtO 2 ,Rh/Al 2 O 3 and Ni-Raney can also be used.
• propanol, tetrahydrofuran and dioxane are also suitable besides methanol and ethanol.
• the catalyst was filtered and washed with awater/methanol (1/1) mixture (300 ml) and the filtrate, combined with the washings, concentrated under vacuum at 40°C until all the methanol has been removed.
• the final suspension was cooled for 20 hours at 0-4°C and the precipitate was filtered and washed on the filter with 70 ml precooled water at 0-4°C.
• (+)-(1S,2R)-2-[[N-(2-hydroxylamino-2-oxoethyI)-N-methylamino ⁇ carbonyl]cyclohexane-1 -carboxylic acid 1 were added and the mixture was further vigorously stirred for 60 minutes at 20°C.
• the light suspension thus obtained was filtered (on paper) and the filtrate was concentrated under vacuum at 40°C to 200 mL.
• the precipitated product was filtered and washed on filter with 50 mL of precooled water at 0-4°C.
• Sample preparation Dissolve 20 mg of sample substance in 100 ml H 2 O/CH 3 CN 80/20
• Table 1 shows the results, and in the first column, the data for the acid 1, tested in the same way, are reported.
• the salts of the invention are also, within the suitable dosage ratios, practically comparable either for potency and for the activity lasting time to the acid 1.
• the salts of this invention constitute the active ingredients for preparing pharmaceutical compositions both for oral and parenteral use.
• compositions and preparations are made with the well-known pharmaceutical techniques and employing conventional excipients, carriers and solvents.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=11361409

Family Applications (1)

Country Status (26)

Cited By (3)

Families Citing this family (2)

Citations (1)

• 1991
  • 1991-12-23 IT ITMI913448A patent/IT1252708B/it active IP Right Grant
• 1992
  • 1992-12-12 JP JP5511398A patent/JPH06506002A/ja active Pending
  • 1992-12-12 RU RU9293052414A patent/RU2079489C1/ru active
  • 1992-12-12 HU HU9302389A patent/HUT69287A/hu unknown
  • 1992-12-12 WO PCT/EP1992/002903 patent/WO1993013056A1/en not_active Application Discontinuation
  • 1992-12-12 EP EP92924726A patent/EP0575572A1/en not_active Withdrawn
  • 1992-12-12 BR BR9205652A patent/BR9205652A/pt not_active Application Discontinuation
  • 1992-12-12 AU AU30871/92A patent/AU657591B2/en not_active Ceased
  • 1992-12-12 CA CA002104372A patent/CA2104372A1/en not_active Abandoned
  • 1992-12-21 CZ CS923796A patent/CZ379692A3/cs unknown
  • 1992-12-21 NZ NZ245547A patent/NZ245547A/en unknown
  • 1992-12-21 SK SK3796-92A patent/SK379692A3/sk unknown
  • 1992-12-22 HR HR921454A patent/HRP921454A2/hr not_active Application Discontinuation
  • 1992-12-22 SI SI9200409A patent/SI9200409A/sl unknown
  • 1992-12-22 MA MA23040A patent/MA22749A1/fr unknown
  • 1992-12-23 MX MX9207543A patent/MX9207543A/es unknown
  • 1992-12-23 PL PL92297118A patent/PL169086B1/pl unknown
  • 1992-12-23 LV LVP-92-358A patent/LV10426B/lv unknown
  • 1992-12-23 YU YU110892A patent/YU110892A/sh unknown
  • 1992-12-23 ZA ZA9210004A patent/ZA9210004B/xx unknown
  • 1992-12-23 PT PT101156A patent/PT101156A/pt not_active Application Discontinuation
  • 1992-12-23 TN TNTNSN92117A patent/TNSN92117A1/fr unknown
  • 1992-12-23 CN CN92113839A patent/CN1079474A/zh active Pending
• 1993
  • 1993-08-18 BG BG98050A patent/BG98050A/bg unknown
  • 1993-08-20 FI FI933685A patent/FI933685A0/fi not_active Application Discontinuation
• 1994
  • 1994-05-23 EE EE9400006A patent/EE9400006A/xx unknown

Patent Citations (1)

Also Published As

Similar Documents

Legal Events